Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity
- Sponsor
- Seoul National University Hospital
- Study ID
- NCT06330220
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept Injection [Eylea] — DRUGintravitreal injection
Study Details
Although the number of wet AMD patients with the better visual acuity is increasing, the visual improvement in patients with the better vision may not be so significant after anti-vascular endothelial growth factor (VEGF) treatments because of 'ceiling effect'. The aim of current study is to investigate the improvement of visual function after aflibercept treatments using microperimetry in wet AMD patients with the better baseline visual acuity (≥20/40).
Key Dates
- Start date
- Feb 10, 2021
- Status verified
- Mar 2024
- Primary completion
- Feb 28, 2022
- Completion
- Feb 28, 2022
Study Design
- Enrollment
- 12 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Aflibercept loadingAdministration of 2㎎ intravitreal aflibercept three times monthly after diagnosis
Primary Outcome Measure
Retinal sensitivity change after aflibercept treatment using microperimetry in wet age-related macular degeneration patients [ Time Frame: 12 weeks ]
Related Studies
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- High Resolution Retinal ImagingRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Stem Cell Ophthalmology Treatment Study IIRecruiting · MD Stem Cells · Westport, Connecticut
- A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationPHASE1 · Recruiting · Astellas Institute for Regenerative Medicine · Phoenix, Arizona